The purpose of the Histopathology and Experimental Animal Facility is to provide the following services in support of by the scientific needs of members of the KCCC: (1) Specialized facilities (e.g., segregated housing, exhaust/containment systems) and specialized animals care, as well as expertise in experimental design and conduct and expert technical assistance for the following types of experiments: animal studies with delivery to wide range of animal species of carcinogenic/toxic chemicals, infectious agents (e.g., challenge experiments), intervention compounds (e.g., chemoprevention or anti- cancer drugs), using inhalation, parenteral, dermal and oral administration routes of exposure. (2) Segregated housing and health monitoring of animals that do not yet have a proven VAF status or that carry transplantable tumors that have not yet been MAP tested; work with these types of animals is not possible in the Centralized Animal Facility. (3) Necropsy services including appropriate tissue fixation required for these animal experiments. (4) High quality histology services geared towards the experimental needs of KCCC members, including: paraffin processing and slide preparation, cryostat sectioning, preparation of slides for immunohistochemistry and in situ hybridization and PCR, plastic embedding and slide preparation, routine conventional and (immuno)histochemical staining, capability to apply special non-routine staining procedures. (5) Basic scanning electron microscopy (sample preparation and microscopy), transmission and electron microscopy (sample preparation only), and morphometry (stereology) services. And (6) Comprehensive consultation and collaboration on carcinogen administration to laboratory animals and experimental pathology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016087-21
Application #
6101774
Study Section
Project Start
1999-05-10
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
21
Fiscal Year
1999
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Gagner, Jean-Pierre; Zagzag, David (2018) Probing Glioblastoma Tissue Heterogeneity with Laser Capture Microdissection. Methods Mol Biol 1741:209-220
Xu, Yang; Taylor, Paul; Andrade, Joshua et al. (2018) Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Res 78:6539-6548
Martin, Patricia K; Marchiando, Amanda; Xu, Ruliang et al. (2018) Autophagy proteins suppress protective type I interferon signalling in response to the murine gut microbiota. Nat Microbiol 3:1131-1141
Tsay, Jun-Chieh J; Wu, Benjamin G; Badri, Michelle H et al. (2018) Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. Am J Respir Crit Care Med 198:1188-1198
Coux, Rémi-Xavier; Teixeira, Felipe Karam; Lehmann, Ruth (2018) L(3)mbt and the LINT complex safeguard cellular identity in the Drosophila ovary. Development 145:
de la Parra, Columba; Ernlund, Amanda; Alard, Amandine et al. (2018) A widespread alternate form of cap-dependent mRNA translation initiation. Nat Commun 9:3068
Fanok, Melania H; Sun, Amy; Fogli, Laura K et al. (2018) Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma. J Invest Dermatol 138:1116-1125
Patibandla, Jay R; Fehniger, Julia E; Levine, Douglas A et al. (2018) Small cell cancers of the female genital tract: Molecular and clinical aspects. Gynecol Oncol 149:420-427
Harper, Lamia; Balasubramanian, Divya; Ohneck, Elizabeth A et al. (2018) Staphylococcus aureus Responds to the Central Metabolite Pyruvate To Regulate Virulence. MBio 9:
Berger, Ashton C; Korkut, Anil; Kanchi, Rupa S et al. (2018) A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33:690-705.e9

Showing the most recent 10 out of 1170 publications